Hepatoprotective mechanism of Silybum marianum on nonalcoholic fatty liver disease based on network pharmacology and experimental verification

References

• Rinella ME. Nonalcoholic fatty liver disease: a systematic review. Jama. 2015;313(22):2263–2273.
   PubMed Web of Science ®Google Scholar
• Diehl AM, Day C, Longo DL. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017;377(21):2063–2072.
   PubMed Web of Science ®Google Scholar
• Wang FS, Fan JG, Zhang Z, et al. The global burden of liver disease: the major impact of China. Hepatology. 2014;60(6):2099–2108.
   PubMed Web of Science ®Google Scholar
• Fan JG, Kim SU, Wong VWS. New trends on obesity and NAFLD in Asia. J Hepatol. 2017;67(4):862–873.
   PubMed Web of Science ®Google Scholar
• Wang MM, Wang GS, Shen F, et al. Hepatic steatosis is highly prevalent in hepatitis B patients and negatively associated with virological factors. Dig Dis Sci. 2014;59(10):2571–2579.
   PubMed Web of Science ®Google Scholar
• Williams CD, Stengel J, Asike MI, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology. 2011;140(1):124–131.
   PubMed Web of Science ®Google Scholar
• Fan JG, Farrell GC. Epidemiology of non-alcoholic fatty liver disease in China. J Hepatol. 2009;50(1):204–210.
   PubMed Web of Science ®Google Scholar
• Vanni E, Bugianesi E. Editorial: utility and pitfalls of fatty liver index in epidemiologic studies for the diagnosis of NAFLD. Alimentary Pharmacology & Therapeutics. 2015;41(4):406–407.
   PubMed Web of Science ®Google Scholar
• Neuschwander-Tetri BA. Non-alcoholic fatty liver disease. BMC Med. 2017;15(1):1–6.
   PubMed Web of Science ®Google Scholar
• Chitturi S, Wong VWS, Chan WK, et al. The Asia–Pacific working party on non‐alcoholic fatty liver disease guidelines 2017—part 2: management and special groups. J Gastroenterol Hepatol. 2018;33(1):86–98.
   PubMed Web of Science ®Google Scholar
• Leoni S, Tovoli F, Napoli L, et al. Current guidelines for the management of non-alcoholic fatty liver disease: a systematic review with comparative analysis. World J Gastroenterol. 2018;24(30):3361.
   PubMed Web of Science ®Google Scholar
• Cai CX, Carlos S, and Solaimani P, et al. Nutritional and dietary interventions for nonalcoholic fatty liver disease. In Ronald Ross Watson and Victor R. Preedy: Dietary Interventions in Liver Disease, (Elsevier Inc.); 2019. p. 357–372. DOI:10.1016/B978-0-12-814466-4.00029-X.
   Google Scholar
• Araújo AR, Rosso N, Bedogni G, et al. Global epidemiology of non‐alcoholic fatty liver disease/non‐alcoholic steatohepatitis: what we need in the future. Liver Int. 2018;38:47–51.
   PubMed Web of Science ®Google Scholar
• Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol. 2019;7(4):313–324.
   PubMed Web of Science ®Google Scholar
• Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig Dis Sci. 2005;50(10):1807–1812.
   PubMed Web of Science ®Google Scholar
• Marmouzi I, Bouyahya A, Ezzat SM, et al. The food plant Silybum marianum (L.) Gaertn.: phytochemistry, ethnopharmacology and clinical evidence. J Ethnopharmacol. 2021;265:113303.
   PubMed Web of Science ®Google Scholar
• Abenavoli L, Izzo AA, Milić N, et al. Milk thistle (Silybum marianum): a concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases. Phytother Res. 2018;32(11):2202–2213.
   PubMed Web of Science ®Google Scholar
• Elateeq AA, Sun Y, Nxumalo W, et al. Biotechnological production of silymarin in Silybum marianum L.: a review. Biocatal Agric Biotechnol. 2020;29:101775.
   Web of Science ®Google Scholar
• Drouet S, Leclerc EA, Garros L, et al. A green ultrasound-assisted extraction optimization of the natural antioxidant and anti-aging flavonolignans from milk thistle Silybum marianum (L.) Gaertn. fruits for cosmetic applications. Antioxidants. 2019;8(8):304.
   Web of Science ®Google Scholar
• Gillessen A, Schmidt HHJ. Silymarin as supportive treatment in liver diseases: a narrative review. Adv Ther. 2020;37(4):1279–1301.
   PubMed Web of Science ®Google Scholar
• Tamayo C, Diamond S. Review of clinical trials evaluating safety and efficacy of milk thistle (Silybum marianum [L.] Gaertn.). Integr Cancer Ther. 2007;6(2):146–157.
   PubMed Web of Science ®Google Scholar
• Stelzer G, Rosen N, Plaschkes I, et al. The GeneCards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. 2016;54(1):1–30.
   PubMedGoogle Scholar
• Piñero J, Ramírez-Anguita JM, Saüch-Pitarch J, et al. The DisGeNET knowledge platform for disease genomics: 2019 update. Nucleic Acids Res. 2020;48(D1):D845–D855.
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets. Nucleic Acids Res. 2021;49(D1):D605–D612.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1–10.
   PubMed Web of Science ®Google Scholar
• Ru J, Li P, Wang J, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6(1):1–6.
   PubMed Web of Science ®Google Scholar
• Kohl M, Wiese S, and Warscheid B. Cytoscape: software for visualization and analysis of biological networks. In Michael HamacherMartin EisenacherChristian Stephan: Data mining in proteomics. Humana Press; 2011. p. 291–303. Springer Nature Switzerland AG. Part of Springer Nature. DOI:10.1007/978-1-60761-987-1_18.
   Google Scholar
• Burley SK, Berman HM, Kleywegt GJ, et al. Protein Data Bank (PDB): the single global macromolecular structure archive. Protein Crystallography. 2017; 627–641. DOI:10.1007/978-1-4939-7000-1_26.
   Google Scholar
• Wang Y, Xiao J, Suzek TO, et al. PubChem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res. 2009;37(suppl_2):W623–W633.
   PubMed Web of Science ®Google Scholar
• Morris GM, Huey R, Lindstrom W, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–2791.
   PubMed Web of Science ®Google Scholar
• Seeliger D, de Groot BL. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des. 2010;24(5):417–422.
   PubMed Web of Science ®Google Scholar
• Liu X, Wu WY, Jiang BH, et al. Pharmacological tools for the development of traditional Chinese medicine. Trends Pharmacol Sci. 2013;34(11):620–628.
   PubMed Web of Science ®Google Scholar
• LaBrecque DR, Abbas Z, Anania F, et al. World Gastroenterology Organisation global guidelines: nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. J Clin Gastroenterol. 2014;48(6):467–473.
   PubMed Web of Science ®Google Scholar
• Asrani SK, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world. J Hepatol. 2019;70(1):151–171.
   PubMed Web of Science ®Google Scholar
• Van De Wier B, Koek GH, Bast A, et al. The potential of flavonoids in the treatment of non-alcoholic fatty liver disease. Crit Rev Food Sci Nutr. 2017;57(4):834–855.
   PubMed Web of Science ®Google Scholar
• Cacciapuoti F, Scognamiglio A, Palumbo R, et al. Silymarin in non alcoholic fatty liver disease. World J Hepatol. 2013;5(3):109.
   PubMedGoogle Scholar
• Zhu SY, Jiang N, Yang J, et al. Silybum marianum oil attenuates hepatic steatosis and oxidative stress in high fat diet-fed mice. Biomed Pharmacother. 2018;100:191–197.
   PubMed Web of Science ®Google Scholar
• Li X, Wang R, Zhou N, et al. Quercetin improves insulin resistance and hepatic lipid accumulation in vitro in a NAFLD cell model. Biomed Rep. 2013;1(1):71–76.
   PubMedGoogle Scholar
• Xu Y, Han J, Dong J, et al. Metabolomics characterizes the effects and mechanisms of quercetin in nonalcoholic fatty liver disease development. Int J Mol Sci. 2019;20(5):1220.
   PubMed Web of Science ®Google Scholar
• Perumpail BJ, Li AA, John N, et al. The role of Vitamin E in the treatment of NAFLD. Diseases. 2018;6(4):86.
   PubMedGoogle Scholar
• Kanwal F, Kramer JR, Mapakshi S, et al. Risk of hepatocellular cancer in patients with non-alcoholic fatty liver disease. Gastroenterology. 2018;155(6):1828–1837.
   PubMed Web of Science ®Google Scholar
• Zhu L, Jiang J, Zhai X, et al. Hepatitis B virus infection and risk of non‐alcoholic fatty liver disease: a population‐based cohort study. Liver Int. 2019;39(1):70–80.
   PubMed Web of Science ®Google Scholar
• Watt MJ, Miotto PM, De Nardo W, et al. The liver as an endocrine organ—linking NAFLD and insulin resistance. Endocr Rev. 2019;40(5):1367–1393.
   PubMed Web of Science ®Google Scholar
• Sartini A, Gitto S, Bianchini M, et al. Non-alcoholic fatty liver disease phenotypes in patients with inflammatory bowel disease. Cell Death Dis. 2018;9(2):1–8.
   PubMed Web of Science ®Google Scholar
• Fang C, Cai X, Hayashi S, et al. Caffeine-stimulated muscle IL-6 mediates alleviation of non-alcoholic fatty liver disease. Biochim Biophys Acta (BBA)-Mol Cell Biol Lipids. 2019;1864(3):271–280.
   PubMed Web of Science ®Google Scholar
• Chen J, Chen J, Fu H, et al. Hypoxia exacerbates nonalcoholic fatty liver disease via the HIF-2α/PPARα pathway. Am J Physiol Endocrinol Metab. 2019;317(4):E710–E722. 2019.
   PubMed Web of Science ®Google Scholar
• Hasenfuss SC, Bakiri L, Thomsen MK, et al. Regulation of steatohepatitis and PPARγ signaling by distinct AP-1 dimers. Cell Metab. 2014;19(1):84–95.
   PubMed Web of Science ®Google Scholar
• Ma X, Liu S, Zhang J, et al. Proportion of NAFLD patients with normal ALT value in overall NAFLD patients: a systematic review and meta-analysis. BMC Gastroenterol. 2020;20(1):1–8.
   Web of Science ®Google Scholar
• Sert A, Pirgon Ö, Aypar E, et al. Relationship between aspartate aminotransferase-to-platelet ratio index and carotid intima-media thickness in obese adolescents with non-alcoholic fatty liver disease. J Clin Res Pediatr Endocrinol. 2013;5(3):182.
   PubMed Web of Science ®Google Scholar
• Hashemi SJ, Hajiani E, Sardabi EH. A placebo-controlled trial of silymarin in patients with nonalcoholic fatty liver disease. Hepatitis Mon. 2009;9(4):265–270. 2009.
   Web of Science ®Google Scholar
• Alves-Bezerra M, Cohen DE. Triglyceride metabolism in the liver. Compr Physiol. 2017;8(1):1.
   PubMed Web of Science ®Google Scholar
• Ren XY, Shi D, Ding J, et al. Total cholesterol to high-density lipoprotein cholesterol ratio is a significant predictor of nonalcoholic fatty liver: jinchang cohort study. Lipids Health Dis. 2019;18(1):1–7.
   PubMed Web of Science ®Google Scholar
• Wang W, Xu AL, Li ZC, et al. Combination of probiotics and salvia miltiorrhiza polysaccharide alleviates hepatic Steatosis via gut microbiota modulation and insulin resistance improvement in high fat-induced NAFLD mice. Diabetes Metab J. 2019;44(2):336–348.
   PubMed Web of Science ®Google Scholar
• Klisic A, Abenavoli L, Fagoonee S, et al. Older age and HDL-cholesterol as independent predictors of liver fibrosis assessed by BARD score. Minerva Med. 2019;110(3):191–198.
   PubMed Web of Science ®Google Scholar
• Sun DQ, Wu SJ, Liu WY, et al. Association of low-density lipoprotein cholesterol within the normal range and NAFLD in the non-obese Chinese population: a cross-sectional and longitudinal study. BMJ open. 2016;6(12):e013781.
   PubMed Web of Science ®Google Scholar
• Tang Z, Pham M, Hao Y, et al. Sex, age, and BMI modulate the association of physical examinations and blood biochemistry parameters and NAFLD: a retrospective study on 1994 cases observed at Shuguang Hospital, China. Biomed Res Int. 2019;1–7. DOI:10.1155/2019/1246518
   Web of Science ®Google Scholar
• Wang G, Luo P, Zhang S, et al. Screening and identification of antidepressant active ingredients from Puerariae Radix extract and study on its mechanism. Oxid Med Cell Longev. 2021;2021:1–8.
   Web of Science ®Google Scholar
• Mao J, Yi M, Wang R, et al. Protective effects of costunolide against D-galactosamine and lipopolysaccharide-induced acute liver injury in mice. Front Pharmacol. 2018;9:1469.
   PubMed Web of Science ®Google Scholar
• Zhang Q, Li Y, Liang T, et al. ER stress and autophagy dysfunction contribute to fatty liver in diabetic mice. Int J Biol Sci. 2015;11(5):559.
   PubMed Web of Science ®Google Scholar
• Ma M, Duan R, Zhong H, et al. The crosstalk between fat homeostasis and liver regional immunity in NAFLD. J Immunol Res. 2019;2019:1–10.
   Web of Science ®Google Scholar